Dupixent CTCL MDL 3180: what the September 10 report may mean for patients

✓ No fee unless you win✓ Free & confidential review✓ Board-certified trial attorney

Last reviewed: September 4, 2026.

The next Dupixent CTCL deadline is a court-management deadline, not a settlement deadline. That distinction matters.

Judge Zahid N. Quraishi's first procedure order requires the lawyers in MDL 3180 to file an Initial Management Report by September 10, 2026. The first in-person management conference is set for October 1 in Trenton, New Jersey.

For families, this is not the moment when the court decides whether Dupixent caused anyone's lymphoma. It is the moment when the court starts building the rules for how the case will move: who speaks for each side, how discovery may be phased, whether new cases can be filed directly into the MDL, and whether the court should use an initial census to collect basic case facts.

Mass Tort America's main Dupixent lawsuit hub explains the larger claim. Plaintiffs allege Sanofi and Regeneron failed to warn that Dupixent may be associated with cutaneous T-cell lymphoma, or may unmask or accelerate CTCL that had been mistaken for eczema. This article is narrower. It looks at the September court step and what patients can do without overreading it.

What the September report may tell us

The June 11 order gives the parties a long agenda. Some of it is routine MDL setup. Some of it could shape the next year of the case.

The report is expected to address leadership counsel, discovery timing, confidentiality orders, possible direct filing of new cases, related lawsuits in other courts, likely pretrial motions, and whether an initial census would help. It also asks the lawyers to identify the main factual and legal issues they expect to fight over.

Those issues are not abstract. The JPML transfer order says the common questions include whether the scientific literature shows a causal link between Dupixent and CTCL, when the defendants should have learned about any link, and whether the warnings were adequate.

In plain English: the MDL is moving from "which court should handle these cases?" to "what rules should govern the early evidence work?"

Why an initial census would matter

Judge Quraishi has not ordered a census yet. The order only asks the parties to address whether one would be useful.

If the court later uses a census, it may ask for the facts that decide whether a claim belongs in the Dupixent CTCL group: proof of Dupixent use, the diagnosis, when symptoms changed, when CTCL was first suspected, whether biopsy or pathology confirmed it, and which doctors treated the patient.

That is why records matter now. Not because a report deadline creates a claim deadline. It does not. Records matter because a person's timeline is usually clearer in pharmacy histories, dermatology notes, pathology reports, oncology records, and insurance records than it is in memory.

People who want their records screened can start with the Dupixent case review form. A review is not a promise that a lawsuit will be filed, and it is not a promise of any result. It is a way to see whether the documented facts fit the litigation being investigated.

Where MDL 3180 stands now

The JPML created MDL No. 3180 on June 4, 2026 and sent the federal Dupixent product-liability cases to the District of New Jersey before Judge Quraishi. The transfer order says the listed cases involved people who used Dupixent and were later diagnosed with CTCL, plus spouses or survivors of Dupixent users diagnosed with CTCL.

The September 1 JPML pending-MDL report lists 35 pending actions and 36 total actions in MDL 3180. Those are docket counts, not medical findings. No bellwether trial has happened. No settlement fund has been announced. No court has made a final ruling on causation or liability.

The current MDL focus is CTCL and CTCL subtypes. The JPML did not decide whether other T-cell lymphoma cases should come in later. Claims involving B-cell lymphoma, Hodgkin lymphoma, or unrelated cancers need a different review and should not be treated as the same thing.

The records that may matter most

The medical literature is careful. Studies have reported an association between dupilumab and CTCL, but they also describe limits: coding problems in databases, small event counts, reporting bias, disease severity differences, and the possibility that early CTCL looked like eczema before Dupixent was started.

A useful file may include:

Dupixent prescription and fill records, including specialty-pharmacy records.
Dermatology records from before and after Dupixent started.
Photos or chart notes showing whether the rash improved, returned, spread, or changed.
Biopsy, immunohistochemistry, T-cell clonality, blood flow cytometry, and oncology records, if those tests were done.
The first date a doctor mentioned CTCL, mycosis fungoides, Sezary syndrome, or another T-cell lymphoma.

Do not stop taking Dupixent, skip injections, or change cancer or dermatology care because of a lawsuit article. Medication decisions belong with your doctor. Legal review should follow the medical record, not replace medical care.

What to watch after September 10

The September 10 report may not answer much by itself. The October 1 conference is the next date to watch because it may lead to a first case-management order. That order could set rules for leadership, discovery, direct filing, preservation, or census work.

For now, the practical step is modest: keep the records that show what happened and when. If you are comparing this case with other active litigations, Mass Tort America's active mass torts page keeps the current list in one place. You can also read about the attorney-review process on the Mass Tort America about page.

FAQ

Is September 10 a filing deadline for patients?

No. The September 10 date comes from Judge Quraishi's initial procedure order and applies to the parties' Initial Management Report. Individual filing deadlines depend on state law, diagnosis dates, and other facts.

Does the September report mean a settlement is close?

No. The report is an early management step. The MDL still has no bellwether trial result, no settlement fund, and no final ruling on whether Dupixent caused or accelerated CTCL in any individual case.

What diagnoses are most relevant to MDL 3180 right now?

The MDL currently focuses on cutaneous T-cell lymphoma and CTCL subtypes, including mycosis fungoides and Sezary syndrome. The JPML left questions about other T-cell lymphomas for possible future transfer proceedings.

Should I change my medication because of this litigation?

No. Talk with your doctor before changing or stopping any prescription medication. If symptoms are changing or worsening, ask your dermatologist or oncologist what testing is appropriate.

Sources

Attorney advertising. This article is general information, not medical advice and not legal advice for any specific person. Prior results do not guarantee a similar outcome. Submitting information for review does not create an attorney-client relationship.

Robert B. Baker, Board-Certified Civil Trial Attorney

Claims reviewed by Baker Legal Team
Robert B. Baker, Esq., B.C.S. — Board-Certified Civil Trial Lawyer. 30+ years of trial experience, more than $400 million recovered for clients. About Robert Baker →